🔬 Study Overview: A meta-analysis comparing alternative LDL cholesterol-lowering strategies (moderate-intensity statins + ezetimibe) vs high-intensity statins in patients with ASCVD.

📊 Key Findings:

✅ No significant difference in 3-year cardiovascular events (7.5% vs 7.7%)

📉 Lower LDL cholesterol in the alternative strategy (64.8 vs 68.5 mg/dL)

🩸 Reduced risk of new-onset diabetes (10.2% vs 11.9%)

💊 Fewer therapy discontinuations due to intolerance (4.0% vs 6.7%)

⚖️ Conclusion: The alternative strategy offers comparable efficacy with better tolerability and safety, making it a viable option for patients intolerant to high-intensity statins.